BioXcel Therapeutics (BTAI) Misses Q1 EPS by 22c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.84), $0.22 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $447.1 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal